HER2 amplification and clinicopathological characteristics in a large Asian cohort of rare mucinous ovarian cancer
Mucinous epithelial ovarian cancer has a poor prognosis in the advanced stages and responds poorly to conventional chemotherapy. We aim to elucidate the clinicopathological factors and incidence of HER2 expression of this cancer in a large Asian retrospective cohort from Singapore. Of a total of 133...
Gespeichert in:
Veröffentlicht in: | PloS one 2013-04, Vol.8 (4), p.e61565 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | 4 |
container_start_page | e61565 |
container_title | PloS one |
container_volume | 8 |
creator | Chay, Wen-Yee Chew, Sung-Hock Ong, Whee-Sze Busmanis, Inny Li, Xinyun Thung, Sharyl Ngo, Lynette Lim, Sheow-Lei Lim, Yong-Kuei Chia, Yin-Nin Koh, Elisa Pang, Cindy Soh, Lay-Tin Wang, Jin Ho, Tew-Hong Tay, Sun-Kuie Lim-Tan, Soo-Kim Lim, Kiat-Hon Chia, John Whay-Kuang Goh, Liang-Kee |
description | Mucinous epithelial ovarian cancer has a poor prognosis in the advanced stages and responds poorly to conventional chemotherapy. We aim to elucidate the clinicopathological factors and incidence of HER2 expression of this cancer in a large Asian retrospective cohort from Singapore. Of a total of 133 cases, the median age at diagnosis was 48.3 years (range, 15.8-89.0 years), comparatively younger than western cohorts. Most were Chinese (71%), followed by Malays (16%), others (9.0%), and Indians (5%). 24% were noted to have a significant family history of malignancy of which breast and gastrointestinal cancers the most prominent. Majority of the patients (80%) had stage I disease at diagnosis. Information on HER2 status was available in 113 cases (85%). Of these, 31 cases (27.4%) were HER2+, higher than 18.8% reported in western population. HER2 positivity appeared to be lower among Chinese and higher among Malays patients (p = 0.052). With the current standard of care, there was no discernible impact of HER2 status on overall survival. (HR = 1.79; 95% CI, 0.66-4.85; p = 0.249). On the other hand, positive family history of cancer, presence of lymphovascular invasion, and ovarian surface involvements were significantly associated with inferior overall survival on univariate and continued to be statistically significant after adjustment for stage. While these clinical factors identify high risk patients, it is promising that the finding of a high incidence of HER2 in our Asian population may allow development of a HER2 targeted therapy to improve the management of mucinous ovarian cancers. |
doi_str_mv | 10.1371/journal.pone.0061565 |
format | Article |
fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_1343847811</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A478215385</galeid><doaj_id>oai_doaj_org_article_ccc75852edbd4af88b50cfb78610698c</doaj_id><sourcerecordid>A478215385</sourcerecordid><originalsourceid>FETCH-LOGICAL-c692t-6f10a5c63fcb679c5205c89607637b5e36483533eab5391bcd81ff9f2ab1f4c53</originalsourceid><addsrcrecordid>eNqNkm-L1DAQxoso3rn6DUQLguCLXZumSds3wnKc3sLBwfnnbZhOkzZLNlmT9tBvb_a2d2xBQfKiYeY3TyczT5K8JtmK0JJ83LrRWzCrvbNylWWcMM6eJOekpvmS5xl9enI_S16EsM0yRivOnydnOY3RkvPzxF9d3uYp7PZGK40waGdTsG2KRluNbg9D74zrYsqk2IMHHKTXYdAYUh3R1IDvZLoOGmyKrnd-SJ1KPXiZ7kbU1o0hdXfg7_NgUfqXyTMFJshX03eRfP98-e3ianl982Vzsb5eIq_zYckVyYAhpwobXtbI8oxhVfPYNy0bJikvKsooldAwWpMG24ooVascGqIKZHSRvD3q7o0LYhpXEIQWtCrKipBIbI5E62Ar9l7vwP8WDrS4DzjfCfDxqUYKRCxZxXLZNm0BqqoalqFqyoqTjNcVRq1P09_GZidblHbwYGai84zVvejcnaCckjxuapG8mwS8-znKMPyj5YnqIHalrXJRDHc6oFhHIidxxYenr_5CxdPKXdyqlUrH-Kzgw6wgMoP8NXQwhiA2X2__n735MWffn7C9BDP0wZnx4LMwB4sjiN6F4KV6nBzJxMHvD9MQB7-Lye-x7M3p1B-LHgxO_wCrXPwk</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1343847811</pqid></control><display><type>article</type><title>HER2 amplification and clinicopathological characteristics in a large Asian cohort of rare mucinous ovarian cancer</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><source>Public Library of Science (PLoS)</source><creator>Chay, Wen-Yee ; Chew, Sung-Hock ; Ong, Whee-Sze ; Busmanis, Inny ; Li, Xinyun ; Thung, Sharyl ; Ngo, Lynette ; Lim, Sheow-Lei ; Lim, Yong-Kuei ; Chia, Yin-Nin ; Koh, Elisa ; Pang, Cindy ; Soh, Lay-Tin ; Wang, Jin ; Ho, Tew-Hong ; Tay, Sun-Kuie ; Lim-Tan, Soo-Kim ; Lim, Kiat-Hon ; Chia, John Whay-Kuang ; Goh, Liang-Kee</creator><creatorcontrib>Chay, Wen-Yee ; Chew, Sung-Hock ; Ong, Whee-Sze ; Busmanis, Inny ; Li, Xinyun ; Thung, Sharyl ; Ngo, Lynette ; Lim, Sheow-Lei ; Lim, Yong-Kuei ; Chia, Yin-Nin ; Koh, Elisa ; Pang, Cindy ; Soh, Lay-Tin ; Wang, Jin ; Ho, Tew-Hong ; Tay, Sun-Kuie ; Lim-Tan, Soo-Kim ; Lim, Kiat-Hon ; Chia, John Whay-Kuang ; Goh, Liang-Kee</creatorcontrib><description>Mucinous epithelial ovarian cancer has a poor prognosis in the advanced stages and responds poorly to conventional chemotherapy. We aim to elucidate the clinicopathological factors and incidence of HER2 expression of this cancer in a large Asian retrospective cohort from Singapore. Of a total of 133 cases, the median age at diagnosis was 48.3 years (range, 15.8-89.0 years), comparatively younger than western cohorts. Most were Chinese (71%), followed by Malays (16%), others (9.0%), and Indians (5%). 24% were noted to have a significant family history of malignancy of which breast and gastrointestinal cancers the most prominent. Majority of the patients (80%) had stage I disease at diagnosis. Information on HER2 status was available in 113 cases (85%). Of these, 31 cases (27.4%) were HER2+, higher than 18.8% reported in western population. HER2 positivity appeared to be lower among Chinese and higher among Malays patients (p = 0.052). With the current standard of care, there was no discernible impact of HER2 status on overall survival. (HR = 1.79; 95% CI, 0.66-4.85; p = 0.249). On the other hand, positive family history of cancer, presence of lymphovascular invasion, and ovarian surface involvements were significantly associated with inferior overall survival on univariate and continued to be statistically significant after adjustment for stage. While these clinical factors identify high risk patients, it is promising that the finding of a high incidence of HER2 in our Asian population may allow development of a HER2 targeted therapy to improve the management of mucinous ovarian cancers.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0061565</identifier><identifier>PMID: 23620766</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Adenocarcinoma, Mucinous - genetics ; Adenocarcinoma, Mucinous - pathology ; Adolescent ; Adult ; Age ; Aged ; Aged, 80 and over ; Asian Continental Ancestry Group - genetics ; Breast cancer ; Cancer ; Cancer therapies ; Chemotherapy ; Children & youth ; Cohort Studies ; Diagnosis ; Disease-Free Survival ; ErbB-2 protein ; Family ; Family medical history ; Female ; Gastric cancer ; Gene Amplification ; Genetics ; Gynecology ; Histopathology ; Humans ; Incidence ; Lymphatic system ; Malignancy ; Medical diagnosis ; Medicine ; Metastasis ; Middle Aged ; Obstetrics ; Oncology ; Ovarian cancer ; Ovarian carcinoma ; Ovarian Neoplasms - genetics ; Ovarian Neoplasms - pathology ; Pathology ; Patients ; Prognosis ; Receptor, ErbB-2 - genetics ; Risk factors ; Singapore ; Statistical analysis ; Stomach cancer ; Studies ; Survival ; Tumors ; Womens health ; Young Adult</subject><ispartof>PloS one, 2013-04, Vol.8 (4), p.e61565</ispartof><rights>COPYRIGHT 2013 Public Library of Science</rights><rights>2013 Chay et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License: https://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2013 Chay et al 2013 Chay et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c692t-6f10a5c63fcb679c5205c89607637b5e36483533eab5391bcd81ff9f2ab1f4c53</citedby><cites>FETCH-LOGICAL-c692t-6f10a5c63fcb679c5205c89607637b5e36483533eab5391bcd81ff9f2ab1f4c53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3631219/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3631219/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,2096,2915,23845,27901,27902,53766,53768,79569,79570</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23620766$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chay, Wen-Yee</creatorcontrib><creatorcontrib>Chew, Sung-Hock</creatorcontrib><creatorcontrib>Ong, Whee-Sze</creatorcontrib><creatorcontrib>Busmanis, Inny</creatorcontrib><creatorcontrib>Li, Xinyun</creatorcontrib><creatorcontrib>Thung, Sharyl</creatorcontrib><creatorcontrib>Ngo, Lynette</creatorcontrib><creatorcontrib>Lim, Sheow-Lei</creatorcontrib><creatorcontrib>Lim, Yong-Kuei</creatorcontrib><creatorcontrib>Chia, Yin-Nin</creatorcontrib><creatorcontrib>Koh, Elisa</creatorcontrib><creatorcontrib>Pang, Cindy</creatorcontrib><creatorcontrib>Soh, Lay-Tin</creatorcontrib><creatorcontrib>Wang, Jin</creatorcontrib><creatorcontrib>Ho, Tew-Hong</creatorcontrib><creatorcontrib>Tay, Sun-Kuie</creatorcontrib><creatorcontrib>Lim-Tan, Soo-Kim</creatorcontrib><creatorcontrib>Lim, Kiat-Hon</creatorcontrib><creatorcontrib>Chia, John Whay-Kuang</creatorcontrib><creatorcontrib>Goh, Liang-Kee</creatorcontrib><title>HER2 amplification and clinicopathological characteristics in a large Asian cohort of rare mucinous ovarian cancer</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>Mucinous epithelial ovarian cancer has a poor prognosis in the advanced stages and responds poorly to conventional chemotherapy. We aim to elucidate the clinicopathological factors and incidence of HER2 expression of this cancer in a large Asian retrospective cohort from Singapore. Of a total of 133 cases, the median age at diagnosis was 48.3 years (range, 15.8-89.0 years), comparatively younger than western cohorts. Most were Chinese (71%), followed by Malays (16%), others (9.0%), and Indians (5%). 24% were noted to have a significant family history of malignancy of which breast and gastrointestinal cancers the most prominent. Majority of the patients (80%) had stage I disease at diagnosis. Information on HER2 status was available in 113 cases (85%). Of these, 31 cases (27.4%) were HER2+, higher than 18.8% reported in western population. HER2 positivity appeared to be lower among Chinese and higher among Malays patients (p = 0.052). With the current standard of care, there was no discernible impact of HER2 status on overall survival. (HR = 1.79; 95% CI, 0.66-4.85; p = 0.249). On the other hand, positive family history of cancer, presence of lymphovascular invasion, and ovarian surface involvements were significantly associated with inferior overall survival on univariate and continued to be statistically significant after adjustment for stage. While these clinical factors identify high risk patients, it is promising that the finding of a high incidence of HER2 in our Asian population may allow development of a HER2 targeted therapy to improve the management of mucinous ovarian cancers.</description><subject>Adenocarcinoma, Mucinous - genetics</subject><subject>Adenocarcinoma, Mucinous - pathology</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Age</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Asian Continental Ancestry Group - genetics</subject><subject>Breast cancer</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>Children & youth</subject><subject>Cohort Studies</subject><subject>Diagnosis</subject><subject>Disease-Free Survival</subject><subject>ErbB-2 protein</subject><subject>Family</subject><subject>Family medical history</subject><subject>Female</subject><subject>Gastric cancer</subject><subject>Gene Amplification</subject><subject>Genetics</subject><subject>Gynecology</subject><subject>Histopathology</subject><subject>Humans</subject><subject>Incidence</subject><subject>Lymphatic system</subject><subject>Malignancy</subject><subject>Medical diagnosis</subject><subject>Medicine</subject><subject>Metastasis</subject><subject>Middle Aged</subject><subject>Obstetrics</subject><subject>Oncology</subject><subject>Ovarian cancer</subject><subject>Ovarian carcinoma</subject><subject>Ovarian Neoplasms - genetics</subject><subject>Ovarian Neoplasms - pathology</subject><subject>Pathology</subject><subject>Patients</subject><subject>Prognosis</subject><subject>Receptor, ErbB-2 - genetics</subject><subject>Risk factors</subject><subject>Singapore</subject><subject>Statistical analysis</subject><subject>Stomach cancer</subject><subject>Studies</subject><subject>Survival</subject><subject>Tumors</subject><subject>Womens health</subject><subject>Young Adult</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><sourceid>DOA</sourceid><recordid>eNqNkm-L1DAQxoso3rn6DUQLguCLXZumSds3wnKc3sLBwfnnbZhOkzZLNlmT9tBvb_a2d2xBQfKiYeY3TyczT5K8JtmK0JJ83LrRWzCrvbNylWWcMM6eJOekpvmS5xl9enI_S16EsM0yRivOnydnOY3RkvPzxF9d3uYp7PZGK40waGdTsG2KRluNbg9D74zrYsqk2IMHHKTXYdAYUh3R1IDvZLoOGmyKrnd-SJ1KPXiZ7kbU1o0hdXfg7_NgUfqXyTMFJshX03eRfP98-e3ianl982Vzsb5eIq_zYckVyYAhpwobXtbI8oxhVfPYNy0bJikvKsooldAwWpMG24ooVascGqIKZHSRvD3q7o0LYhpXEIQWtCrKipBIbI5E62Ar9l7vwP8WDrS4DzjfCfDxqUYKRCxZxXLZNm0BqqoalqFqyoqTjNcVRq1P09_GZidblHbwYGai84zVvejcnaCckjxuapG8mwS8-znKMPyj5YnqIHalrXJRDHc6oFhHIidxxYenr_5CxdPKXdyqlUrH-Kzgw6wgMoP8NXQwhiA2X2__n735MWffn7C9BDP0wZnx4LMwB4sjiN6F4KV6nBzJxMHvD9MQB7-Lye-x7M3p1B-LHgxO_wCrXPwk</recordid><startdate>20130419</startdate><enddate>20130419</enddate><creator>Chay, Wen-Yee</creator><creator>Chew, Sung-Hock</creator><creator>Ong, Whee-Sze</creator><creator>Busmanis, Inny</creator><creator>Li, Xinyun</creator><creator>Thung, Sharyl</creator><creator>Ngo, Lynette</creator><creator>Lim, Sheow-Lei</creator><creator>Lim, Yong-Kuei</creator><creator>Chia, Yin-Nin</creator><creator>Koh, Elisa</creator><creator>Pang, Cindy</creator><creator>Soh, Lay-Tin</creator><creator>Wang, Jin</creator><creator>Ho, Tew-Hong</creator><creator>Tay, Sun-Kuie</creator><creator>Lim-Tan, Soo-Kim</creator><creator>Lim, Kiat-Hon</creator><creator>Chia, John Whay-Kuang</creator><creator>Goh, Liang-Kee</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PIMPY</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQGLB</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20130419</creationdate><title>HER2 amplification and clinicopathological characteristics in a large Asian cohort of rare mucinous ovarian cancer</title><author>Chay, Wen-Yee ; Chew, Sung-Hock ; Ong, Whee-Sze ; Busmanis, Inny ; Li, Xinyun ; Thung, Sharyl ; Ngo, Lynette ; Lim, Sheow-Lei ; Lim, Yong-Kuei ; Chia, Yin-Nin ; Koh, Elisa ; Pang, Cindy ; Soh, Lay-Tin ; Wang, Jin ; Ho, Tew-Hong ; Tay, Sun-Kuie ; Lim-Tan, Soo-Kim ; Lim, Kiat-Hon ; Chia, John Whay-Kuang ; Goh, Liang-Kee</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c692t-6f10a5c63fcb679c5205c89607637b5e36483533eab5391bcd81ff9f2ab1f4c53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adenocarcinoma, Mucinous - genetics</topic><topic>Adenocarcinoma, Mucinous - pathology</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Age</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Asian Continental Ancestry Group - genetics</topic><topic>Breast cancer</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>Children & youth</topic><topic>Cohort Studies</topic><topic>Diagnosis</topic><topic>Disease-Free Survival</topic><topic>ErbB-2 protein</topic><topic>Family</topic><topic>Family medical history</topic><topic>Female</topic><topic>Gastric cancer</topic><topic>Gene Amplification</topic><topic>Genetics</topic><topic>Gynecology</topic><topic>Histopathology</topic><topic>Humans</topic><topic>Incidence</topic><topic>Lymphatic system</topic><topic>Malignancy</topic><topic>Medical diagnosis</topic><topic>Medicine</topic><topic>Metastasis</topic><topic>Middle Aged</topic><topic>Obstetrics</topic><topic>Oncology</topic><topic>Ovarian cancer</topic><topic>Ovarian carcinoma</topic><topic>Ovarian Neoplasms - genetics</topic><topic>Ovarian Neoplasms - pathology</topic><topic>Pathology</topic><topic>Patients</topic><topic>Prognosis</topic><topic>Receptor, ErbB-2 - genetics</topic><topic>Risk factors</topic><topic>Singapore</topic><topic>Statistical analysis</topic><topic>Stomach cancer</topic><topic>Studies</topic><topic>Survival</topic><topic>Tumors</topic><topic>Womens health</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chay, Wen-Yee</creatorcontrib><creatorcontrib>Chew, Sung-Hock</creatorcontrib><creatorcontrib>Ong, Whee-Sze</creatorcontrib><creatorcontrib>Busmanis, Inny</creatorcontrib><creatorcontrib>Li, Xinyun</creatorcontrib><creatorcontrib>Thung, Sharyl</creatorcontrib><creatorcontrib>Ngo, Lynette</creatorcontrib><creatorcontrib>Lim, Sheow-Lei</creatorcontrib><creatorcontrib>Lim, Yong-Kuei</creatorcontrib><creatorcontrib>Chia, Yin-Nin</creatorcontrib><creatorcontrib>Koh, Elisa</creatorcontrib><creatorcontrib>Pang, Cindy</creatorcontrib><creatorcontrib>Soh, Lay-Tin</creatorcontrib><creatorcontrib>Wang, Jin</creatorcontrib><creatorcontrib>Ho, Tew-Hong</creatorcontrib><creatorcontrib>Tay, Sun-Kuie</creatorcontrib><creatorcontrib>Lim-Tan, Soo-Kim</creatorcontrib><creatorcontrib>Lim, Kiat-Hon</creatorcontrib><creatorcontrib>Chia, John Whay-Kuang</creatorcontrib><creatorcontrib>Goh, Liang-Kee</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest Health & Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health & Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Applied & Life Sciences</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chay, Wen-Yee</au><au>Chew, Sung-Hock</au><au>Ong, Whee-Sze</au><au>Busmanis, Inny</au><au>Li, Xinyun</au><au>Thung, Sharyl</au><au>Ngo, Lynette</au><au>Lim, Sheow-Lei</au><au>Lim, Yong-Kuei</au><au>Chia, Yin-Nin</au><au>Koh, Elisa</au><au>Pang, Cindy</au><au>Soh, Lay-Tin</au><au>Wang, Jin</au><au>Ho, Tew-Hong</au><au>Tay, Sun-Kuie</au><au>Lim-Tan, Soo-Kim</au><au>Lim, Kiat-Hon</au><au>Chia, John Whay-Kuang</au><au>Goh, Liang-Kee</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>HER2 amplification and clinicopathological characteristics in a large Asian cohort of rare mucinous ovarian cancer</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2013-04-19</date><risdate>2013</risdate><volume>8</volume><issue>4</issue><spage>e61565</spage><pages>e61565-</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Mucinous epithelial ovarian cancer has a poor prognosis in the advanced stages and responds poorly to conventional chemotherapy. We aim to elucidate the clinicopathological factors and incidence of HER2 expression of this cancer in a large Asian retrospective cohort from Singapore. Of a total of 133 cases, the median age at diagnosis was 48.3 years (range, 15.8-89.0 years), comparatively younger than western cohorts. Most were Chinese (71%), followed by Malays (16%), others (9.0%), and Indians (5%). 24% were noted to have a significant family history of malignancy of which breast and gastrointestinal cancers the most prominent. Majority of the patients (80%) had stage I disease at diagnosis. Information on HER2 status was available in 113 cases (85%). Of these, 31 cases (27.4%) were HER2+, higher than 18.8% reported in western population. HER2 positivity appeared to be lower among Chinese and higher among Malays patients (p = 0.052). With the current standard of care, there was no discernible impact of HER2 status on overall survival. (HR = 1.79; 95% CI, 0.66-4.85; p = 0.249). On the other hand, positive family history of cancer, presence of lymphovascular invasion, and ovarian surface involvements were significantly associated with inferior overall survival on univariate and continued to be statistically significant after adjustment for stage. While these clinical factors identify high risk patients, it is promising that the finding of a high incidence of HER2 in our Asian population may allow development of a HER2 targeted therapy to improve the management of mucinous ovarian cancers.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>23620766</pmid><doi>10.1371/journal.pone.0061565</doi><tpages>e61565</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1932-6203 |
ispartof | PloS one, 2013-04, Vol.8 (4), p.e61565 |
issn | 1932-6203 1932-6203 |
language | eng |
recordid | cdi_plos_journals_1343847811 |
source | MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Free Full-Text Journals in Chemistry; Public Library of Science (PLoS) |
subjects | Adenocarcinoma, Mucinous - genetics Adenocarcinoma, Mucinous - pathology Adolescent Adult Age Aged Aged, 80 and over Asian Continental Ancestry Group - genetics Breast cancer Cancer Cancer therapies Chemotherapy Children & youth Cohort Studies Diagnosis Disease-Free Survival ErbB-2 protein Family Family medical history Female Gastric cancer Gene Amplification Genetics Gynecology Histopathology Humans Incidence Lymphatic system Malignancy Medical diagnosis Medicine Metastasis Middle Aged Obstetrics Oncology Ovarian cancer Ovarian carcinoma Ovarian Neoplasms - genetics Ovarian Neoplasms - pathology Pathology Patients Prognosis Receptor, ErbB-2 - genetics Risk factors Singapore Statistical analysis Stomach cancer Studies Survival Tumors Womens health Young Adult |
title | HER2 amplification and clinicopathological characteristics in a large Asian cohort of rare mucinous ovarian cancer |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-17T17%3A25%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=HER2%20amplification%20and%20clinicopathological%20characteristics%20in%20a%20large%20Asian%20cohort%20of%20rare%20mucinous%20ovarian%20cancer&rft.jtitle=PloS%20one&rft.au=Chay,%20Wen-Yee&rft.date=2013-04-19&rft.volume=8&rft.issue=4&rft.spage=e61565&rft.pages=e61565-&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0061565&rft_dat=%3Cgale_plos_%3EA478215385%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1343847811&rft_id=info:pmid/23620766&rft_galeid=A478215385&rft_doaj_id=oai_doaj_org_article_ccc75852edbd4af88b50cfb78610698c&rfr_iscdi=true |